New hope for rare stomach cancer: drug cocktail shows promise in early trial

NCT ID NCT07178340

Recruiting now Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of chemotherapy drugs and an immunotherapy drug for a rare and aggressive type of stomach cancer called hepatoid adenocarcinoma. About 30 people with locally advanced, HER2-negative cancer will receive the treatment before and after surgery. The goal is to see if this approach can shrink tumors and improve outcomes, while also checking for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOID ADENOCARCINOMA OF STOMACH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatoid adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOID ADENOCARCINOMA OF STOMACH

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University Cancer Hospital & Institute
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••